Thromboxane b2

Thromboxane b2 is a lipid of Fatty Acyls (FA) class. Thromboxane b2 is associated with abnormalities such as endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia and Thrombocytosis. The involved functions are known as Platelet Activation, Excretory function, Anabolism, Inflammation and mRNA Expression. Thromboxane b2 often locates in Endothelium, Hepatic and Microsomes, Liver. The associated genes with Thromboxane b2 are PTGS2 gene, prothrombin fragment 2 and CCL14 wt Allele.

Cross Reference

Introduction

To understand associated biological information of Thromboxane b2, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Thromboxane b2?

Thromboxane b2 is suspected in endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia, Thrombocytosis, Acute Coronary Syndrome and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Thromboxane b2

MeSH term MeSH ID Detail
Granulomatosis with Polyangiitis D014890 5 associated lipids
Ductus Arteriosus, Patent D004374 5 associated lipids
Placenta Diseases D010922 5 associated lipids
Intracranial Embolism and Thrombosis D002542 5 associated lipids
Facial Pain D005157 5 associated lipids
Hypoalphalipoproteinemias D052456 5 associated lipids
Abortion, Habitual D000026 5 associated lipids
Mastocytosis D008415 5 associated lipids
Bartter Syndrome D001477 5 associated lipids
Aortic Aneurysm, Abdominal D017544 5 associated lipids
Hypercapnia D006935 5 associated lipids
Asthenia D001247 5 associated lipids
Respiration Disorders D012120 5 associated lipids
Glomerulonephritis, Membranous D015433 6 associated lipids
Coronary Stenosis D023921 6 associated lipids
Sneezing D012912 6 associated lipids
Bronchitis D001991 6 associated lipids
Intermittent Claudication D007383 6 associated lipids
Purpura, Thrombotic Thrombocytopenic D011697 6 associated lipids
Thromboembolism D013923 6 associated lipids
Per page 10 20 50 100 | Total 293

PubChem Associated disorders and diseases

What pathways are associated with Thromboxane b2

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Thromboxane b2?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Thromboxane b2?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Thromboxane b2?

There are no associated biomedical information in the current reference collection.

What genes are associated with Thromboxane b2?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Thromboxane b2?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with Thromboxane b2

Download all related citations
Per page 10 20 50 100 | Total 6367
Authors Title Published Journal PubMed Link
Schorer AE Discordant effects on eicosanoids and fibrin degradation products in two murine models of antiphospholipid antibody. 1997 Thromb. Res. pmid:9062953
Weide I and Simmet T Leukotriene formation by peripheral monocytes in contact-activated human blood. 1993 Thromb. Res. pmid:8211886
Saldeen P et al. Increased synthesis of thromboxane B2 and 6-keto-PGF1 alpha in hand veins from patients with deep venous thrombosis. 1983 Thromb. Res. pmid:6658723
Bradlow BA and Chetty N Dosage frequency for suppression of platelet function by low dose aspirin therapy. 1982 Thromb. Res. pmid:7123514
Carroll RC et al. Post interventional cardiology urinary thromboxane correlates with PlateletMapping detected aspirin resistance. 2010 Thromb. Res. pmid:19962724
Ziegler BK et al. Incomplete thromboxane inhibition with 100 mg of intravenous acetylsalicylic acid in patients with acute ST elevation myocardial infarction: a placebo-controlled pilot trial. 2001 Thromb. Res. pmid:11672759
Ersöz G et al. The effect of submaximal exercise on platelet aggregation during late follicular and midluteal phases in women. 2002 Thromb. Res. pmid:12590951
Martin JF et al. Effect of acetylsalicylic acid on platelet aggregation and thromboxane B2 production in flowing aortic blood in the rat studied with a filter loop technique. 1982 Thromb. Res. pmid:6814004
Mikashima H and Muramoto Y Protective effect of Y-20811, a long-lasting thromboxane synthetase inhibitor, on endotoxin shock in rabbits. 1990 Thromb. Res. pmid:2326771
Agren JJ et al. Dose responses in platelet fatty acid composition, aggregation and prostanoid metabolism during moderate freshwater fish diet. 1990 Thromb. Res. pmid:2326774
Kawamura M et al. Evaluation of plasma 11-dehydro-thromboxane B2 as an indicator for thromboxane A2 synthesis in vivo in laboratory animals. 1995 Thromb. Res. pmid:7778061
Winter M et al. Synthesis of thromboxane B2 in uraemia and the effects of dialysis. 1983 Thromb. Res. pmid:6868024
Ersöz G et al. Effect of sodium selenite treatment on platelet aggregation of streptozotocin-induced diabetic rats. 2003 Thromb. Res. pmid:14698654
Huang CG et al. Effect of berberine on arachidonic acid metabolism in rabbit platelets and endothelial cells. 2002 Thromb. Res. pmid:12297129
Teng CM et al. Two antiplatelet agents from Magnolia officinalis. 1988 Thromb. Res. pmid:3413728
Grauso F et al. Effects of iloprost (ZK 36374), a prostacyclin derivative, on platelet function after ischaemic exercise in patients with stable angina pectoris. 1987 Thromb. Res. pmid:2447664
Vlodavsky I et al. Platelet interaction with the extracellular matrix produced by cultured endothelial cells: a model to study the thrombogenicity of isolated subendothelial basal lamina. 1982 Thromb. Res. pmid:7179215
Udvardy M et al. Plasma thromboxane and prostacyclin metabolite ratio in atherosclerosis and diabetes mellitus. 1987 Thromb. Res. pmid:3116717
Cholette JM et al. Aspirin resistance following pediatric cardiac surgery. 2010 Thromb. Res. pmid:20550971
García Frade LJ et al. Diabetes mellitus as a hypercoagulable state: its relationship with fibrin fragments and vascular damage. 1987 Thromb. Res. pmid:3118498
Carter AJ et al. Human pulmonary vessels obtained from necropsy produce less prostacyclin and thromboxane than fresh vessels obtained from operations. 1984 Thromb. Res. pmid:6547546
Hernández R et al. Influence of co-incubation and cell number of platelets and polymorphonuclear leukocytes in cellular inhibition and activation phenomena. 1994 Thromb. Res. pmid:8042192
Tsuboi T et al. Effect of gliclazide on prostaglandin and thromboxane synthesis in guinea-pig platelets. 1981 Jan 1-15 Thromb. Res. pmid:7233394
Hanasaki K and Arita H Characterization of a new compound, S-145, as a specific TXA2 receptor antagonist in platelets. 1988 Thromb. Res. pmid:2839912
Ditter H et al. Effects of prostacyclin during cardiopulmonary bypass in men on plasma levels of beta-thromboglobulin, platelet factor 4, thromboxane B2, 6-keto-prostaglandin F1 alpha and heparin. 1983 Thromb. Res. pmid:6197766
Shorr RI et al. In vitro effects of acetaminophen and its analogues on human platelet aggregation and thromboxane B2 synthesis. 1985 Thromb. Res. pmid:3923647
Ishikawa Y et al. Effect of cytoplasmic pH on platelet activation by arachidonic acid. 1989 Thromb. Res. pmid:2499076
Lages B and Weiss HJ Inhibition of human platelet function in vitro and ex vivo by acetaminophen. 1989 Thromb. Res. pmid:2499947
Dalli E et al. Effects of hawthorn (Crataegus laevigata) on platelet aggregation in healthy volunteers. 2011 Thromb. Res. pmid:21737127
Toivanen J et al. Differential inhibition of platelet thromboxane and lung prostacyclin production by sulphinpyrazone, acetylsalicylic acid and indomethacin by human tissues in vitro. 1985 Thromb. Res. pmid:3920778
Ishii H et al. The effect of plasma on platelet function in hypercholesterolemic rabbits and the changes in fatty acid composition of the plasma. 1984 Thromb. Res. pmid:6234679
Reimers HJ et al. Impaired thromboxane synthesis in preactivated human blood platelets: agonist-specific, irreversible desensitization to thrombin. 1987 Thromb. Res. pmid:3126557
Stegmeier K et al. The pharmacological profile of the thromboxane A2 antagonist BM 13.177. A new anti-platelet and anti-thrombotic drug. 1984 Thromb. Res. pmid:6385334
Mercer JB et al. The effect of short-term cold exposure on risk factors for cardiovascular disease. 1999 Thromb. Res. pmid:10418798
Perneby C et al. Prothrombotic responses to exercise are little influenced by clopidogrel treatment. 2004 Thromb. Res. pmid:15381386
Hall ER et al. The reduction of platelet thrombi on damaged vessel wall by a thromboxane synthetase inhibitor in rabbits. 1982 Thromb. Res. pmid:6891109
Lukasik M et al. Aspirin treatment influences platelet-related inflammatory biomarkers in healthy individuals but not in acute stroke patients. 2011 Thromb. Res. pmid:21788065
Gerrard JM et al. Studies in patients with bleeding disorders show that platelet-vessel interaction is important for thromboxane formation in bleeding time wounds. 1990 Thromb. Res. pmid:2278038
Wang JP et al. Antiplatelet effect of capsaicin. 1984 Thromb. Res. pmid:6528310
Udvardy M et al. Alterations of primary haemostasis in mixed connective tissue disease (MCTD). 1991 Thromb. Res. pmid:1835548
Lin CH et al. HA-29: an inhibitor of thromboxane A2 formation with antagonism of thromboxane A2/prostaglandin endoperoxide receptor in rabbit platelets. 1992 Thromb. Res. pmid:1412184
Tindall H et al. Thrombin generation precedes platelet activation in native blood taken from the hand during multiple blood sampling following cold challenge. 1987 Thromb. Res. pmid:3617016
Mannucci L et al. Indobufen is a potent inhibitor of whole blood aggregation in patients with a high atherosclerotic risk. 1987 Thromb. Res. pmid:3445229
Nosál' R et al. Chloroquine: a multipotent inhibitor of human platelets in vitro. 2000 Thromb. Res. pmid:10828481
Chakroun T et al. Screening for aspirin resistance in stable coronary artery patients by three different tests. 2007 Thromb. Res. pmid:17553552
Simmet T and Luck W Clotting of whole human blood induces cysteinyl-leukotriene formation. 1989 Thromb. Res. pmid:2549655
Buchanan MR et al. The sex-related differences in aspirin pharmacokinetics in rabbits and man and its relationship to antiplatelet effects. 1983 Thromb. Res. pmid:6221436
Randall MJ and Wilding RI Acute arterial thrombosis in rabbits: reduced platelet accumulation after treatment with thromboxane synthetase inhibitor dazoxiben hydrochloride, (UK-37, 248-01). 1982 Thromb. Res. pmid:6897751
Di Minno G and Violi F Aspirin resistance and diabetic angiopathy: back to the future. 2004 Thromb. Res. pmid:15115664
Best LC et al. Mode of action of dipyridamole on human platelets. 1979 Thromb. Res. pmid:229583
Zijlstra FJ et al. Thrombotic thrombocytopenic purpura and plasma thromboxane B2 levels. 1983 Thromb. Res. pmid:6684333
Kudolo GB et al. Effect of the ingestion of Ginkgo biloba extract on platelet aggregation and urinary prostanoid excretion in healthy and Type 2 diabetic subjects. 2002 Thromb. Res. pmid:12590952
Maderna P et al. Differential effects of oral administrations to human volunteers of acetylsalicylic acid, sodium salicylate and indomethacin on 12-hydroxyeicosatetraenoic acid formation by stimulated platelets. 1988 Thromb. Res. pmid:3194896
Todd MK et al. Effect of exercise intensity on 6-keto-PGF1 alpha, TXB2, and 6-keto-PGF1 alpha/TXB2 ratios. 1992 Thromb. Res. pmid:1615492
Dembinska-Kiec A et al. Ticlopidine and platelet function in healthy volunteers. 1992 Thromb. Res. pmid:1615496
Platelet function during long-term treatment with ketanserin of claudicating patients with peripheral atherosclerosis. A multi-center, double-blind, placebo-controlled trial. The PACK Trial Group. 1989 Thromb. Res. pmid:2528841
Hashimoto Y et al. Characteristics of protein kinase C-independent exocytosis in human platelets. 1997 Thromb. Res. pmid:9336873
Yue TL et al. Pharmacological profile of G619, a new platelet aggregation inhibitor. 1992 Thromb. Res. pmid:1412200
Russell NH et al. Platelet adenine nucleotides and arachidonic acid metabolism in the myeloproliferative disorders. 1981 Thromb. Res. pmid:6794179
Thorwest M et al. Dietary fish oil reduces microvascular thrombosis in a porcine experimental model. 2000 Thromb. Res. pmid:10946095
Dupin JP et al. In vitro antiaggregant activity of paracetamol and derivatives. 1988 Thromb. Res. pmid:3134743
Martin JF et al. The biological significance of platelet volume: its relationship to bleeding time, platelet thromboxane B2 production and megakaryocyte nuclear DNA concentration. 1983 Thromb. Res. pmid:6658722
Saloheimo P et al. Thromboxane and prostacyclin biosynthesis in patients with acute spontaneous intracerebral hemorrhage. 2005 Thromb. Res. pmid:15733969
Chiang TM and Kang AH The effect of platelet surface protein phosphorylation on collagen-platelet interaction. 1986 Thromb. Res. pmid:3810565
Serebruany VL and Gurbel PA Assessment of platelet activity by measuring platelet-derived substances in plasma from patients with acute myocardial infarction: surprising lessons from the GUSTO-III Platelet Study. 1999 Thromb. Res. pmid:10030832
Kelton JG et al. A study of the bioavailability and platelet inhibitory effects of a new enteric-coated acetylsalicylic acid preparation. 1984 Thromb. Res. pmid:6740573
Grimm LJ et al. Inhibition of platelet thromboxane synthesis by 7-(1-imidazolyl) heptanoic acid: dissociation from inhibition of aggregation. 1981 Thromb. Res. pmid:6801806
Uyama O et al. Plasma concentrations of 6-keto-prostaglandin F1 alpha in patients with hypertension, cerebrovascular disease or Takayasu's arteritis. 1982 Jan 1-15 Thromb. Res. pmid:6121391
Hashizume T et al. Vinblastine inhibits platelet aggregation by a microtubule-independent mechanism, probably by its perturbing action on the plasma membrane. 1988 Thromb. Res. pmid:3135636
Chou TC et al. The inhibitory effect of 2-thienyl 2'-hydroxyphenyl ketone (C85) on platelet thromboxane formation. 1996 Thromb. Res. pmid:8897698
Teng CM et al. Antiplatelet actions of some coumarin compounds isolated from plant sources. 1992 Thromb. Res. pmid:1523611
Knapp HR et al. Effects of low-dose aspirin on endogenous eicosanoid formation in normal and atherosclerotic men. 1988 Thromb. Res. pmid:3293263
Pinto S et al. No signs of increased thrombin generation in menopause. 1990 Thromb. Res. pmid:2201101
Randall MJ et al. UK-37, 248, a novel, selective thromboxane synthetase inhibitor with platelet anti-aggregatory and anti-thrombotic activity. 1981 Jul 1-15 Thromb. Res. pmid:6795753
De Caterina R et al. Inhibition of platelet aggregation and thromboxane B2 production during aspirin treatment: dependence on the dose of the aggregating agent. 1985 Thromb. Res. pmid:3975876
Worthington RE and Fuller GC Dibutyryl cyclic guanosine monophosphate elevates bovine endothelial cell thromboxane production without affecting prostacyclin metabolism. 1984 Thromb. Res. pmid:6322377
Kritz H et al. Isradipine increases vascular prostaglandin I2-formation while the thromboxane B2-synthesis is diminished. 1995 Thromb. Res. pmid:8610276
Armstrong RA et al. No effect of dietary trans isomers of alpha-linolenic acid on platelet aggregation and haemostatic factors in european healthy men. The TRANSLinE study. 2000 Thromb. Res. pmid:11108899
De Caterina R et al. Long-term maintenance of thromboxane inhibition by two different aspirin regimens in patients with unstable angina. 1990 Thromb. Res. pmid:2126400
Bergqvist D et al. The effect of inhibition of thromboxane synthesis in experimental thrombosis and hemostasis. 1985 Thromb. Res. pmid:3838828
Kelton JG et al. Sex-related differences in the efficacy of acetylsalicylic acid (ASA) : the absorption of ASA and its effect on collagen-induced thromboxane B2 generation. 1981 Oct 1-15 Thromb. Res. pmid:7330835
De La Cruz JP et al. Effect of DT-TX 30, a combined thromboxane synthase inhibitor and thromboxane receptor antagonist, on retinal vascularity in experimental diabetes mellitus. 2000 Thromb. Res. pmid:10680643
Domoto DT et al. Combined aspirin and sulfinpyrazone in the prevention of recurrent hemodialysis vascular access thrombosis. 1991 Thromb. Res. pmid:1926064
Wang JP et al. XC 386: a new antiplatelet agent. 1984 Thromb. Res. pmid:6438827
Shatoor AS et al. Effect of Hawthorn (Crataegus aronia syn. Azarolus (L)) on platelet function in albino Wistar rats. 2012 Thromb. Res. pmid:22261477
Driss F et al. Inhibition of platelet aggregation and thromboxane synthesis after intake of small amount of icosapentaenoic acid. 1984 Thromb. Res. pmid:6098051
Vila V et al. Fibrinopeptide A release from intraplatelet fibrinogen is related to thrombin platelet activation. 1997 Thromb. Res. pmid:9175247
Carter AJ and Jones EW The effect of the degree of diabetic control on thromboxane synthesis in clotted whole blood. 1986 Thromb. Res. pmid:3515613
Mogensen F et al. Effect of specific thromboxane-synthetase inhibition on thromboxane and prostaglandin synthesis in stable angina induced by exercise test. 1985 Thromb. Res. pmid:4038824
Tzeng SH et al. Inhibition of platelet aggregation by some flavonoids. 1991 Thromb. Res. pmid:1776142
Antonino MJ et al. Antiplatelet effects of aspirin with phytosterols: comparison with non-enteric coated aspirin alone. 2010 Thromb. Res. pmid:19446864
Neiman J et al. Platelet uptake of serotonin (5-HT) during ethanol withdrawal in male alcoholics. 1987 Thromb. Res. pmid:2820078
Zahavi M et al. Enhanced platelet release reaction and increased thromboxane generation in esophageal achalasia and selective in vitro inhibition of arachidonic acid induced platelet aggregation by vasoactive intestinal peptide. 1990 Thromb. Res. pmid:2146767
Simmet T and Weide I Thromboxane and cysteinyl-leukotriene formation are differentially activated in spontaneously clotting whole human blood in vitro. 1991 Thromb. Res. pmid:1866709
Weigel G et al. Regulation of eicosanoid release in human umbilical endothelial cells. 1991 Thromb. Res. pmid:1656543
Ko FN et al. Antiplatelet effects of protopine isolated from Corydalis tubers. 1989 Thromb. Res. pmid:2559491
Lukaszyk A et al. Blood platelet function in canine acute pancreatitis with reference to treatment with Nafamostat mesilate (FUT-175). 1992 Thromb. Res. pmid:1579898
Meyers KM et al. An evaluation of the arachidonate pathway of platelets from companion and food-producing animals, mink, and man. 1980 Thromb. Res. pmid:7209869
Grignani G et al. Activation of platelet prostaglandin biosynthesis pathway during neoplastic cell-induced platelet aggregation. 1984 Thromb. Res. pmid:6729776
Patterson WR et al. Aggregation of killer whale platelets. 1993 Thromb. Res. pmid:8327987